Interim report
Page 1
August 01, 2026 To To The Secretary The Secretary National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Trading Symbol: DIVISLAB Scrip Code: 532488 Dear Sir / Madam, Sub: Outcome of Board Meeting held on August 01, 2026 Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 Fur ther to our letter dated July 20, 2026, we would like to inform that the Board of Directors of the Company at its meeting held on August 01, 2026, has approved, inter alia, the following items of business: Fin ancial Results Approved the unaudited financial results for the quarter ended June 30, 2026. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following: 1. Sta tement of unaudited standalone financial results for the quarter ended June 30, 2026 and Limited Review Report of the Statutory Auditors thereon. 2. Statement of unaudited consolidated financial results for the quarter ended June 30, 2026, and Limited Review Report of the Statutory Auditors thereon. 3. Press release on financial results. Appo intment of Senior Management Personnel Approved appointment of Mr. B. Vara Prasad, General Manager (Engineering Purch ase) and Mr. J. Srinivasa Rao, Gen eral Manager (Raw Mater ials Purchase) as Senior Management Personnel of the Company as recommended by the Nomination and Remuneration Committee, with effect from August 01, 2026. The details required under Regulation 30 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is en closed as Annexure – I. @!i) Divi 's Laboratories Limited Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA. Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854 E-mail: mail@divislabs.com, Website: www.divislabs.com
Page 2
T he Board meeting commenced at 10.15 Hrs and concluded at 11.20 Hrs. T his is for your information and records. T hanking you, Yours faithfully, For Divi's Laboratories Limited M . Satish Choudhury Company Secretary & Compliance Officer @!i) Divi 's Laboratories Limited Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA. Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854 E-mail: mail@divislabs.com, Website: www.divislabs.com
Page 3
DIVl'S LABORATORIES LIMITED STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2026 s. 30.06.2026 No. Particulars (Unaudited) 1 Income Revenue from operations 2974 Other income 63 Total income 3037 2 Exoenses a) Cost of materials consumed 1495 b) Purchases of stock-in-trade - c) Changes in inventories of finished goods, work-in- (567) progress, and stock-in-trade d) Employee benefits exoense 397 e) Depreciation and amortization expense 132 f) Finance costs 6 g) Other expenses 409 Total expenses 1872 3 Profit before exceotional items and tax {1-2) 1165 4 Exceptional items - Impact of New Labour codes - 5 Profit before tax (3-4) 1165 6 Tax expense a) Current tax 290 b) Deferred tax (16) Total tax expense 274 7 Profit for the period (5-6) 891 8 Other comorehensive income: Items that will not be reclassified to Profit or Loss: (i) Gain/(Loss) on Remeasurement of 2 post-employment benefit obligation (ii) Income tax relating to the above (I) Total other comprehensive income (i+ii) 1 9 Total comprehensive income (7+8) 892 10 Paid-up Equitv Share Capital 53 11 Other equity excluding revaluation reserve 12 Earnings per Share# (Face Value Rs.2/- each) (not annualized) a) Basic (Rs.) 33.55 b) Diluted (Rs.) 33.55 # Eammgs per share calculated on actual amount of profit after tax in rupees * Amount is below the rounding off norms adopted by the company. Notes: (tin Crores Quarter ended Year ended 31 .03.2026 30.06.2025 31.03.2026 (Audited)** (Unaudited) (Audited) 2793 2357 10388 154 119 506 2947 2476 10894 1173 989 4260 - - - (70) (72) (244) 370 330 1400 120 112 461 6 3 23 377 367 1484 1976 1729 7384 971 747 3510 - - 74 971 747 3436 250 191 869 (35) (1) (40) 215 190 829 756 557 2607 (8) (I) 8 2 -* (2) (6) (I) 6 750 556 2613 53 53 53 16658 28.44 20.95 98.19 28.44 20.95 98.19 1. The above Statement of standalone unaudited financial results for the quarter ended 30th June, 2026 ("Standalone statement") is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Standalone statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 01, 2026. The statutory auditors have carried out a limited review of the Standalone statement and issued an unmodified report thereon. 2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108. 3. The Company does not have any discontinued operations and the profit for the period represents profits from continuing operations only. 4. **Financial results for the quarter ended 31.03.2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year, which were subjected to limited review. 5. Details offorex gain/(loss) are as given below: (t in Crores) Quarter Ended Year Ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026
Page 4
Price Waterhouse Chartered Accountants LLP Review Report To The Board of Directors M/s Divi's Laboratories Limited Divi Towers, 1-72/23(P)/303, Cyber Hills, Gachibowli, Hyderabad, 500032 1. We have reviewed the standalone unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended June 30, 2026, which are included in the accompanying "Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2026" (the "Standalone Statement"). The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This Standalone Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Standalone Statement based on our review. 2. We conducted our review of the Standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For Price Waterhouse Chartered Accountants LLP Firm Registration Number: 012754N/N500016 ~~-""- N.K. Varadarajan Partner Membership Number UDIN Place of signature Date : 90196 : 26090196DKUQIF1056 : Hyderabad : August 01, 2026 Price Waterhouse Chartered Accountants Ll.P, Unit - 2B, 8th Floor, Octave Block, Block El, Parcel - 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081 T: +91(40)44246740 Registered office and Head office: 11-A. Vishnu Oigamber Marg, Sucheta Bhawan, New Delhi - 110002 Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP Identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post Its conversion to Price Waterhouse Chartered Accountants LLP, Its ICAJ registration number Is 012754N/N500016 (ICAI registration number before conversion was 012754N)
Page 5
DIVl'S LABORATORIES LIMITED STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2026 (f in Crores) s. Quarter ended Year ended No Particulars 30.06.2026 31 .03.2026 30.06.2025 31 .03.2026 (Unaudited) (Audited)** (Unaudited) (Audited) 1 Income Revenue from operations 3080 2831 2410 10560 Other income 64 155 119 507 Total income 3144 2986 2529 11067 2 Expenses a) Cost of materials consumed 1503 1214 1010 4378 b) Purchases of stock-in-trade - - - - c) Changes in inventories of finished goods, work-in- progress and stock-in-trade (517) (95) (54) (285) d) Employee benefits expense 408 381 340 1442 e) Depreciation and amortization expense 133 120 112 463 f) Finance costs 6 6 3 23 g) Other expenses 431 397 385 1584 Total expenses 1964 2023 1796 7605 3 Profit before exceptional items and tax (1-2) 1180 963 733 3462 4 Exceptional items - Impact of new Labour codes - - - 74 5 Profit before tax (3-4) 1180 963 733 3388 6 Tax expense a) Current tax 291 249 191 868 b) Deferred tax (13) (37) (3) (48) Total tax expense 278 212 188 820 7 Profit for the period (5-6) 902 751 545 2568 8 Profit for the period attributable to: Shareholders of the Company 902 751 545 2568 Non-controlling interest - - - - 9 Other comprehensive income: a) Items that will not be reclassified to profit or loss: i) Gain/(loss) on Remeasurement of post-employment benefit obligations 2 (8) (1) 8 ii) Income tax relating to the above (1) 2 -* (2) b) Items that will be reclassified to profit or loss: i) Gain on exchange differences in translating the financial statements of foreign operations I 7 4 20 ii) Income tax relating to the above -* (2) -* (5) Total Other comprehensive income/(loss) (a+b) 2 (1) 3 21 10 Total Other comprehensive income for the period attributable to: Shareholders of the Company 2 (1) 3 21 Non-controlling interest - - - - 11 Total comprehensive income for the period (7+9) 904 750 548 2589 12 Total comprehens ive income for the period attributable to: Shareholders of the company 904 750 548 2589 Non-controlling interest - - - - 13 Paid-up Equity Share Capital 53 53 53 53 14 Other equity excluding revaluation reserves 16708 15 Earnings per Share # (of Rs.2/- each) (not annualized) .. ~-.~~-· - ~~•~ ..... ~.~" a) Basic (Rs.) 33.95 28.31 20.49 ;< 't,U'9'61Y)' / . •,;;. b) Diluted (Rs.) --~ ~ 33.95 28.31 20.49/ -~i 96.75 · ~ ~ )'"' ·- · 'co ~ 10 .LJ ,,,. o:~•-··1···· , , , .... , ,._ ~ · t~ ..... ''✓ ~· • - nt .. : -··, # Earnings per share calc>~ _ on a'c a'I amounr o. J:lrott 3(1 ~ :ax in rupees ~ .\.. * Amount is below the ro eJ gp ff n~ · opt~ by t~e t~ . ··o,, . . . .. • ., ;;"' o oo~ '° ~ - --:~et 12, s •• ~J/ so o"" * Hydc raba.ci *
Page 6
NOTES: 1. The above Statement of consolidated unaudited financial results for the quarter ended 30th June, 2026 ("Consolidated statement") is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Consolidated statement has been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on August 01, 2026. The statutory auditors have carried out a limited review of the Consolidated statement and issued an unmodified report thereon. 2. The consolidated financial results include the financial results ofDivi's Laboratories Limited and its wholly owned subsidiaries Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG (Referred as the "Group"). 3. The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reporting business segment as per Ind AS 108. 4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only. 5. **Financial results for the quarter ended 31.03.2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year, which were subjected to limited review. 6. Details ofForex gain/(loss) are as given below: (i in Crores) Quarter Ended Year Ended 30.06.2026 I 31.03.2026 I 30.06.2025 31.03.2026 Forex gain/(loss) (7) I 90 I 39 211 Forex gain has been included in other income and loss has been included in other expenses. Place: Hyder Date: August For Divi's Laboratories Limited Dr. Kiran S Divi Whole-time Director and Chief Executive Officer
Page 7
Price Waterhouse Chartered Accountants LLP Review Report To The Board of Directors M/s Divi's Laboratories Limited Divi Towers, 1-72/23(P)/303, Cyber Hills, Gachibowli, Hyderabad, 500032 1. We have reviewed the consolidated unaudited financial results of Divi's Laboratories Limited (the "Parent") and its subsidiaries (the Parent and its subsidiaries hereinafter referred to as the "Group"), (refer Note 2 on the Consolidated Statement) for the quarter ended June 30, 2026 which are included in the accompanying "Statement of Consolidated Unaudited Financial Results for the quarter ended June 30, 2026 " (the "Consolidated Statement"). The Consolidated Statement is being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015") which has been initialled by us for identification purposes. 2. This Consolidated Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") , prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India . Our responsibility is to express a conclusion on the Consolidated Statement based on our review. 3. We conducted our review of the Consolidated Statement in accordance with the Standard on Review Engagements ('SRE') 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 4. The Consolidated Statement includes the results of the following entities: a) Divis Laboratories (USA) Inc. b) Divi's Laboratories Europe AG Price Waterhouse Chartered Accountants Ll..P, Unit - 2B, 8th Floor, Octave Block, Block El, Parcel - 4, Salarpuria Sattva Knowledge City, Raidurg , Hyderabad , Telangana - 500081 T: +91 (40) 44246740 Registered office and Hsad office : 11-A. Vishnu Digamber Marg, Sucheta Bhawan, New Deihl - 110002 Price Waterhouse (a Partne rship Firm) converted into Price Waterhou se Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post Its conversion to Price Waterhouse Chartered Accountants LLP, Its ICAI registration number Is 012754N/N500016 (ICAI registration numbar before conversion was 012754N)
Page 8
Price Waterhouse Chartered Accountants LLP 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For Price Waterhouse Chartered Accountants LLP Firm Registration Number: 012754N/N500016 N.K. Varadarajan Partner Membership Number UDIN Place of signature Date : 90196 : 26090196BAZFGH6329 : Hyderabad : August 01, 2026
Page 9
@ DIVl'S LABO RA TORIES LIMITED CIN: L24110TG1990PLC011854 Registered Office: 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India, Phone: +91 40 66966300, email: cs@divislabs.com, website: www.divislabs.com PRESS RELEASE DATED 151 August 2026 Divi's Laboratories earns a Consolidated Total Income oft 3144 Crores for Ql of Financial Year 2026-27 Consolidated Financial Results For the quarter ended 30th June 2026 Divi' s Laboratories Limited has earned a consolidated total income oft 3, 144 crores for the quarter ended 30th June 2026 as against a consolidated total income oft 2,529 crores for the corresponding quarter of the previous financial year. Profit before tax (PBT) for the quarter amounted to t 1,180 crores as against a PBT of t 733 crores for the corresponding quarter of the previous financial year. Profit after tax (PAT) for the quarter amounted to t 902 crores as against a PAT of t 545 crores for the corresponding quarter of the previous financial year. For the current quarter, we have a forex loss oft 7 crores as against a forex gain oft 3 9 crores for the corresponding quarter of the previous financial year. Standalone Financial Results On a standalone basis, the Company's earnings are as given below: ~ in crores Particulars For the Quarter ended 30-06-2026 30-06-2025 Total Income 3037 2476 Profit Before Tax 1165 747 Tax Expense 274 190 Profit After Tax 891 557 Forex gain/ loss for the period, on standalone basis, is as given below: ~ in crores Particulars For the Quarter ended 30-06-2026 30-06-2025 Forex Gain/(Loss) (7) 39
Page 10
Approved inclusion of Senior Management: ANNEXURE – I S.No Particulars Details 1 Name Mr. B. Vara Prasad Mr. J. Srinivasa Rao 2 Reason for change viz. appointment, re- appointment, resignation, removal, death or otherwise; Mr. Vara Prasad working as General Manager (Engineering Purchase) , has been appointed as Senior Management Personnel with effect from August 01, 2026. Mr. Srinivasa Rao working as General Manager (Raw Materials Purchase), has been appointed as Senior Management Personnel with effect from August 01, 2026. 3 Date of appointment August 01, 2026 August 01, 2026 4 Brief profile Mr. Vara Prasad holds a master’s degree in business administration . He joined Divi’s Laboratories Limited in the year 1994. With over 31 years of experience in the pharmaceutical industry, he is a highly accomplished Supply Chain and Procurement professional. Over the course of his career, he has played a pivotal role in managing the procurement of high-value capital equipment and in coordinating the development and commissioning of new manufacturing facilities. He brings deep domain expertise in strategic sourcing, vendor management, contract negotiations, and large - scale project execution. He is widely recognized for his ability to lead cross -functional procurement teams and drive key initiatives related to energy-efficient equipment, adoption of new technologies, and sustainable energy systems. H e is currently responsible for all engineering related procurement in the Company Mr. Srinivasa Rao holds a master’s degree in business administration. He joined Divi’s Laboratories Limited in the year 1995. He is a highly skilled professional with over 30 years of experience in managing and optimizing procurement operations in the pharmaceutical industry. He has proven track record in managing procurement of domestic and import raw materials, annual contracts and leading large procurement team. He has experience in strategic sourcing, vendor development, contract negotiation, regulatory compliance and c ross-functional coordination. He is acclaimed for his contributions for implementation of diversified and sustainable supply chain. He is currently responsible for end-to-end raw materials procurement in the Company. 5 Disclosure of relationship between directors Nil Nil @!i) Divi 's Laboratories Limited Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA. Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854 E-mail: mail@divislabs.com, Website: www.divislabs.com